Raza Shahzad, Chaudhry Naueen A, Brown Jordan D, Aghaie Sina, Rezai Damoun, Khan Areej, Tan Paul De Leon, Berger Barbara J
Department of Internal Medcine, Brookdale University Hospital and Medical Center, New York, NY, USA.
J Clin Med Res. 2013 Feb;5(1):12-7. doi: 10.4021/jocmr1040w. Epub 2013 Jan 11.
Pancreatitis complicating HIV infection, even in the Highly Active Antiretroviral Therapy (HAART) era, remains a management challenge. We felt there is a need to discern patterns in the biochemical markers, radiological studies, co-infections, length of stay (LOS) in patients with HIV or AIDS AND pancreatitis.
This is a retrospective study conducted from June, 2008 to August, 2010 on patients admitted with acute pancreatitis to our hospital. We extracted and compared the following parameters: biochemical markers, HBV markers (surface antigen, core antibody and surface antibody), HCV antibody, radiological studies, and length of stay (LOS). The Balthazar Grade score was used to assess radiological severity of disease. We stratified the cohort into comparison subsets according to CD4 count.
Ninety-four admissions met the criteria for HIV or AIDS AND pancreatitis; 67 unique patients comprised the cohort. Median age was 48 years (range, 23 to 60 years). Thirty seven (55%) were male, 30 (45%), female. Two third (n = 51) (76%) were African American. Known risk factors included a history of pancreatitis, 17 (25%); cholecystitis, 13 (19%); alcohol abuse, 25 (37%); Intravenous drug abuse, 18 (27%). Only 36 (38%) admissions were on HAART regimen. Biochemical features on admission were: WBC, 6,100/mm(3) (900 - 25,700); amylase, 152 U/L (30 - 1,344); lipase, 702.5 U/L (30 - 5,766), triglyceride, 65 mg/dL (57 - 400); glucose, 94 mg/dL (60 - 1,670); lactate, 2.3 mmol/L (1.09 - 5.49); AST, 61.5 U/L (9 - 1,950); LDH, 762 U/L (394 - 5,500); bicarbonate 19.5 mEq/L (3.3 - 82.7). Interestingly, 62% patients had normal pancreas on CT scan on admission. Of 67 individuals, hepatitis profile was available in 43, 21 (49%) were positive for HCV, 11 (26%) had markers for HBV. Four of 11 patients (36) with CD4 < 50 had evidence of persistent HBV (+core, -surface ab). Patients with CD4 < 200 have a median time for hospital course of 8 days (range 4 - 61 days) compare to 3 days in patients with CD4 > 200. P = 0.03 via t-test comparison. One patient with CD4 < 50 died due to acute pancreatitis.
Pancreatitis remains a major cause of morbidity in HIV-infected individuals. This study has provided detailed features in the HAART therapy era about the clinical, biochemical and radiological features of pancreatitis. Half of our patients were positive for HCV; additionally, 36% with CD4 < 50 had persistent HBV. As opposed to earlier studies, we did not find a female predominance. Patients with CD4 < 200 had a 2.67-fold increase length of stay. Future studies are needed for a closer look on viral cofactors which might precipitate episodes of acute pancreatitis.
即使在高效抗逆转录病毒治疗(HAART)时代,胰腺炎合并HIV感染仍是一个治疗难题。我们认为有必要识别HIV或艾滋病合并胰腺炎患者的生化指标、影像学检查、合并感染及住院时间(LOS)的模式。
这是一项对2008年6月至2010年8月我院收治的急性胰腺炎患者进行的回顾性研究。我们提取并比较了以下参数:生化指标、乙肝标志物(表面抗原、核心抗体和表面抗体)、丙肝抗体、影像学检查及住院时间(LOS)。采用巴尔萨泽分级评分评估疾病的影像学严重程度。我们根据CD4细胞计数将队列分为比较亚组。
94例入院患者符合HIV或艾滋病合并胰腺炎的标准;队列包括67例独特患者。中位年龄为48岁(范围23至60岁)。37例(55%)为男性,30例(45%)为女性。三分之二(n = 51)(76%)为非裔美国人。已知危险因素包括胰腺炎病史17例(25%);胆囊炎13例(19%);酒精滥用25例(37%);静脉药物滥用18例(27%)。仅36例(38%)入院患者接受HAART治疗方案。入院时的生化特征为:白细胞6,100/mm³(900 - 25,700);淀粉酶152 U/L(30 - 1,344);脂肪酶702.5 U/L(30 - 5,766),甘油三酯65 mg/dL(57 - 400);葡萄糖94 mg/dL(60 - 1,670);乳酸2.3 mmol/L(1.09 - 5.49);谷草转氨酶61.5 U/L(9 - 1,950);乳酸脱氢酶762 U/L(394 - 5,500);碳酸氢盐19.5 mEq/L(3.3 - 82.7)。有趣的是,62%的患者入院时CT扫描显示胰腺正常。67例患者中,43例有肝炎检查结果,21例(49%)丙肝阳性,11例(26%)有乙肝标志物。11例CD4<50的患者中有4例(36%)有持续性乙肝证据(核心抗体阳性,表面抗体阴性)。CD4<200的患者住院病程中位时间为8天(范围4 - 61天),而CD4>200的患者为3天。经t检验比较,P = 0.03。1例CD4<50的患者死于急性胰腺炎。
胰腺炎仍是HIV感染个体发病的主要原因。本研究提供了HAART治疗时代胰腺炎临床、生化和影像学特征的详细信息。我们一半的患者丙肝阳性;此外,36% CD4<50的患者有持续性乙肝。与早期研究不同,我们未发现女性占优势。CD4<200的患者住院时间增加2.67倍。未来需要进一步研究密切关注可能引发急性胰腺炎发作的病毒协同因子。